{
}
UBS AG has maintained a "Neutral" rating for Bayer, with a price target of 30 euros, following insights from CFO Wolfgang Nickl at an investor conference. Despite Bayer shares dropping 3.2% to EUR 20.22, there remains a potential upside of 48.37%. The stock has declined 39.6% since the start of 2024, with Q4 2024 financial results expected on March 5, 2025.
UBS has maintained a 'Neutral' rating for Bayer, with a price target of 30 euros, following insights from a meeting with CFO Wolfgang Nickl. Despite facing short-term challenges, Nickl expressed long-term confidence in the company's prospects. Bayer's sales are primarily derived from agricultural products (48.8%) and pharmaceuticals (38%).
UBS has maintained a "Neutral" rating for Bayer following a meeting with the CFO at an investor conference, with a price target set at 30 euros. Analyst Jo Walton noted Wolfgang Nickl's long-term confidence in the company despite facing increasing short-term challenges.
UBS AG has maintained a "Neutral" rating on Bayer shares, with a price target of 30 euros, following insights from CFO Wolfgang Nickl at an investor conference. Despite Bayer's shares trading down 3.1% to EUR 20.23, they still show a potential growth of 48.33% relative to the target price. The stock has seen a significant decline of 39.6% since the start of 2024, with key Q4 2024 figures expected on March 5, 2025.
UBS AG maintains a "Neutral" rating on Bayer shares, with a price target of 30 euros, despite recent challenges. As of 15:48 in XETRA trading, Bayer shares fell 3.1% to EUR 20.23, indicating a potential growth of 48.33% towards the target price. The stock has declined 39.6% since the start of 2024, with Q4 2024 key figures set to be released on March 5, 2025.
Bayer"s stock plummeted over 12% following disappointing third-quarter results and a downward revision of its 2024 guidance, primarily due to struggles in its agriculture sector. The company reported a net loss of €4.18 billion, driven by significant write-downs in its agrochemicals division, which saw an 8.7% revenue decline. While the Pharmaceuticals and Consumer Health divisions showed some growth, overall expectations for 2024 remain cautious, with anticipated declines in profit and a commitment to cost-cutting measures.
Wolfgang Nickl
People
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
ubs maintains neutral rating for bayer with unchanged price target
16:04 13.11.2024
ubs maintains neutral rating for bayer with target price of 30 euros
15:59 13.11.2024
ubs maintains neutral rating for bayer with unchanged price target
15:11 13.11.2024
ubs maintains neutral rating on bayer shares with unchanged price target
15:04 13.11.2024
ubs maintains neutral rating for bayer shares with unchanged price target
15:04 13.11.2024
bayer reports significant losses and cuts guidance amid agricultural market challenges
13:01 12.11.2024
Trending
Subcategory
Industry Trends
Corporate News
Startups & Entrepreneurship
Global Trade Developments
Retail and Consumer Goods
Supply Chain Management
Government Economic Policies
Workplace Trends
Industry Mergers & Acquisitions
Stock Market Updates
Fintech Startups
Venture Capital Investments
Financial Scams and Security
Finance Mergers & Acquisitions
CEO Changes
Cryptocurrency Trends
Emerging Startups
Cryptocurrency & Blockchain Regulations
Funding Rounds & Investments
Energy Sector Developments
Countries:
Companies:
Apple Inc.
Google Inc.
Alphabet Inc.
NVIDIA Corporation
Tesla, Inc.
Microsoft Corporation
Amazon.com, Inc.
Delhivery Limited
Ecom Express Ltd.
Foxconn Technology Co., Ltd.
Samsung SDI Co., Ltd.
SWIGGY LIMITED
UWS JP Morgan EM A OSB
Netflix, Inc.
Airbnb, Inc.
Adobe Inc.
GEELY AUTO
TENCENT
CarTrade Tech Limited
Concrete Credit Limited
Currencies:
United States Dollar
Indian Rupee
Chinese Yuan
Euro
Japanese Yen
South Korean Won
Algerian Dinar
Vietnamese Đồng
Indonesian Rupiah
Australian Dollar
Egyptian Pound
Saudi Riyal
Swiss Franc
British Pound Sterling
Russian Ruble
Pakistani Rupee
People: